Related Experiment Videos
[Efficacy of continuous isoproterenol inhalation therapy for severe asthma attacks in younger children]
Y Adachi1, A Yoshizumi, T Ikarashi
1Department of Pediatrics, Toyama Medical & Pharmaceutical University.
Insights
Continuous isoproterenol inhalation effectively treats severe asthma attacks in children. While younger children required higher doses and showed slower improvement, the therapy remained beneficial for this age group.
Area of Science:
- Pediatric Pulmonology
- Pharmacotherapy
- Respiratory Medicine
Context:
- Severe asthma attacks in children pose significant clinical challenges.
- Assessing age-specific treatment efficacy is crucial for optimizing pediatric asthma management.
- Continuous inhalation therapy offers a potential treatment modality for severe pediatric asthma.
Purpose:
- To compare the efficacy of continuous isoproterenol inhalation therapy in younger versus older children experiencing severe asthma attacks.
- To evaluate treatment outcomes, including clinical scores, oxygen saturation, and time to improvement.
- To determine optimal dosing strategies based on age groups.
Summary:
- The study evaluated continuous isoproterenol (Proternol L) in 31 children with severe asthma attacks, divided into under-6 (Group A) and over-7 (Group B) age groups.
- Group A showed higher clinical scores, longer improvement times, and required higher isoproterenol doses than Group B, indicating slightly lower efficacy in younger children.
- Despite these differences, continuous isoproterenol inhalation therapy proved effective for both age groups, with only one patient not improving.
Impact:
- Continuous isoproterenol inhalation therapy is a viable treatment option for severe asthma attacks in young children.
- Understanding age-related differences in response and dosage is essential for effective pediatric asthma care.
- This study provides evidence supporting the use of isoproterenol in severe pediatric asthma, guiding clinical practice and future research.
Abstract:
The aim of this study was to evaluate the efficacy of continuous isoproterenol inhalation therapy for severe asthma attacks in younger children, compared with its efficacy in older children. We used l-body isoproterenol (Proternol L) in 31 children with 42 episodes of severe attacks. They were divided into two group according to age: 20 cases under 6 years old (Group A), and 22 cases over 7 years old (Group B). All of the patients except for one in Group B, eventually improved with this therapy. Wood's clinical scores for Group A were significantly higher than those for group B (p < 0.01). In 22 cases whose scores were 5-6, their SpO2 values at the onset of this therapy were 90.8 +/- 3.17 in group A and 92.4 +/- 3.82% in group B. The improvement time of group A (13.6 +/- 16.2 hours) was significantly longer than that of group B (2.5 +/- 5.66, p < 0.01). The nebulized isoproternol doses for group A were 0.47 +/- 0.168 and for group B 0.26 +/- 0.096 mg/kg/saline 500 ml. The dose for group A was significantly higher than that for group B (p < 0.01). We concluded that continuous isoproterenol inhalation therapy was effective even in younger children. But the degree of efficacy was slightly lower in younger children, although they inhaled higher doses of isoproterenal than older children.